The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Open accessAbstract
The T cell co-stimulatory molecule OX40 and its cognate ligand OX40L have attracted broad research interest as a therapeutic target in T cell-mediated diseases. Accumulating preclinical evidence highlights the therapeutic efficacy of both agonist and blockade of the OX40–OX40L interaction. Despite this progress, many questions about the immuno-modulator roles of OX40 on T cell function remain unanswered. In this review we summarize the impact of the OX40–OX40L interaction on T cell subsets, including Th1, Th2, Th9, Th17, Th22, Treg, Tfh, and CD8+ T cells, to gain a comprehensive understanding of anti-OX40 mAb-based therapies. The potential therapeutic application of the OX40–OX40L interaction in autoimmunity diseases and cancer immunotherapy are further discussed; OX40–OX40L blockade may ameliorate autoantigen-specific T cell responses and reduce immune activity in autoimmunity diseases. We also explore the rationale of targeting OX40–OX40L interactions in cancer immunotherapy. Ligation of OX40 with targeted agonist anti-OX40 mAbs conveys activating signals to T cells. When combined with other therapeutic treatments, such as anti-PD-1 or anti-CTLA-4 blockade, cytokines, chemotherapy, or radiotherapy, the anti-tumor activity of agonist anti-OX40 treatment will be further enhanced. These data collectively suggest great potential for OX40-mediated therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Follicular Helper CD4 T Cells (T FH )
Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
Raphael, I., Nalawade, S., Eagar, T. N., & Forsthuber, T. G. (2015) · Cytokine · doi:10.1016/j.cyto.2014.09.011 · Cited by 1,160
Ferber, I. A., Brocke, S., Taylor-Edwards, C., Ridgway, W., Dinisco, C., Steinman, L., Dalton, D., & Fathman, C. G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.5 · Cited by 989
Pathogenesis of systemic lupus erythematosus
Mok, C. C., & Lau, C. S. (2003) · Journal of Clinical Pathology · doi:10.1136/jcp.56.7.481 · Cited by 942
NF-κB-Inducing Kinase Regulates the Processing of NF-κB2 p100
Xiao, G., Harhaj, E. W., & Sun, S.-C. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00187-3 · Cited by 834
Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells
Tang, Q., Henriksen, K. J., Boden, E. K., Tooley, A. J., Ye, J., Subudhi, S. K., Zheng, X. X., Strom, T. B., & Bluestone, J. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3348 · Cited by 670
OX40 Promotes Bcl-xL and Bcl-2 Expression and Is Essential for Long-Term Survival of CD4 T Cells
Rogers, P. R., Song, J., Gramaglia, I., Killeen, N., & Croft, M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00191-1 · Cited by 646
Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo
Gavin, M. A., Clarke, S. R., Negrou, E., Gallegos, A., & Rudensky, A. (2002) · Nature Immunology · doi:10.1038/ni743 · Cited by 640
TH2 cell development and function
Walker, J. A., & McKenzie, A. N. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.118 · Cited by 632
The significance of OX40 and OX40L to T‐cell biology and immune disease
Croft, M., So, T., Duan, W., & Soroosh, P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00766.x · Cited by 604
Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
Croft, M. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101243 · Cited by 548
Nakae, S., Saijo, S., Horai, R., Sudo, K., Mori, S., & Iwakura, Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1035999100 · Cited by 490
Fehérvari, Z., & Sakaguchi, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200423395 · Cited by 452
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428
OX40 costimulation turns off Foxp3+ Tregs
Vu, M. D., Xiao, X., Gao, W., Degauque, N., Chen, M., Kroemer, A., Killeen, N., Ishii, N., & Chang Li, X. (2007) · Blood · doi:10.1182/blood-2007-01-070748 · Cited by 428
Nakae, S., Suto, H., Iikura, M., Kakurai, M., Sedgwick, J. D., Tsai, M., & Galli, S. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2238 · Cited by 412
Gramaglia, I., Jember, A., Pippig, S. D., Weinberg, A. D., Killeen, N., & Croft, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3043 · Cited by 409
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Gri, G., Piconese, S., Frossi, B., Manfroi, V., Merluzzi, S., Tripodo, C., Viola, A., Odom, S., Rivera, J., Colombo, M. P., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.018 · Cited by 391
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 387
The Role of ICOS in the CXCR5+ Follicular B Helper T Cell Maintenance In Vivo
Akiba, H., Takeda, K., Kojima, Y., Usui, Y., Harada, N., Yamazaki, T., Ma, J., Tezuka, K., Yagita, H., & Okumura, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2340 · Cited by 374
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
Young, K. H., Baird, J. R., Savage, T., Cottam, B., Friedman, D., Bambina, S., Messenheimer, D. J., Fox, B., Newell, P., Bahjat, K. S., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157164 · Cited by 325
Kopf, M., Ruedl, C., Schmitz, N., Gallimore, A., Lefrang, K., Ecabert, B., Odermatt, B., & Bachmann, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80144-2 · Cited by 321
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 321
Rationale for anti-OX40 cancer immunotherapy
Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J.-C., Zitvogel, L., & Marabelle, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.021 · Cited by 318
Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells
Takeda, I., Ine, S., Killeen, N., Ndhlovu, L. C., Murata, K., Satomi, S., Sugamura, K., & Ishii, N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3580 · Cited by 308
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.26 · Cited by 284
Baum, P. R., Gayle, R. B., Ramsdell, F., Srinivasan, S., Sorensen, R. A., Watson, M. L., Seldin, M. F., Baker, E., Sutherland, G. R., & Clifford, K. N. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06715.x · Cited by 283
Impairment of Antigen-Presenting Cell Function in Mice Lacking Expression of Ox40 Ligand
Murata, K., Ishii, N., Takano, H., Miura, S., Ndhlovu, L. C., Nose, M., Noda, T., & Sugamura, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.365 · Cited by 283
The IL-2 cytokine family in cancer immunotherapy
Sim, G. C., & Radvanyi, L. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.018 · Cited by 278
OX40, OX40L and Autoimmunity: a Comprehensive Review
Webb, G. J., Hirschfield, G. M., & Lane, P. J. L. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8498-3 · Cited by 277
Weinberg, A. D., Wegmann, K. W., Funatake, C., & Whitham, R. H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1818 · Cited by 252
Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS)
Glatigny, S., & Bettelli, E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028977 · Cited by 247
Chemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242
Linton, P.-J., Bautista, B., Biederman, E., Bradley, E. S., Harbertson, J., Kondrack, R. M., Padrick, R. C., & Bradley, L. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021290 · Cited by 242
Fantini, M. C. (2006) · Gut · doi:10.1136/gut.2005.072801 · Cited by 238
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 238
OX40 signaling favors the induction of TH9 cells and airway inflammation
Xiao, X., Balasubramanian, S., Liu, W., Chu, X., Wang, H., Taparowsky, E. J., Fu, Y.-X., Choi, Y., Walsh, M. C., & Li, X. C. (2012) · Nature Immunology · doi:10.1038/ni.2390 · Cited by 237
Self-citationOX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response
Jacquemin, C., Schmitt, N., Contin-Bordes, C., Liu, Y., Narayanan, P., Seneschal, J., Maurouard, T., Dougall, D., Davizon, E. S., Dumortier, H., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.012 · Cited by 233
Akiba, H., Miyahira, Y., Atsuta, M., Takeda, K., Nohara, C., Futagawa, T., Matsuda, H., Aoki, T., Yagita, H., & Okumura, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.375 · Cited by 233
Hirschhorn-Cymerman, D., Rizzuto, G. A., Merghoub, T., Cohen, A. D., Avogadri, F., Lesokhin, A. M., Weinberg, A. D., Wolchok, J. D., & Houghton, A. N. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082205 · Cited by 227
Graham, D. S. C., Graham, R. R., Manku, H., Wong, A. K., Whittaker, J. C., Gaffney, P. M., Moser, K. L., Rioux, J. D., Altshuler, D., Behrens, T. W., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.47 · Cited by 222
Immunotherapy of cancer by IL-12-based cytokine combinations
Weiss, J. M., Subleski, J. J., Wigginton, J. M., & Wiltrout, R. H. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.11.1705 · Cited by 221
So, T., & Croft, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1427 · Cited by 210
Jember, A. G.-H., Zuberi, R., Liu, F.-T., & Croft, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.3.387 · Cited by 210
Malmström, V., Shipton, D., Singh, B., Al-Shamkhani, A., Puklavec, M. J., Barclay, A. N., & Powrie, F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6972 · Cited by 209
The costimulation-regulated duration of PKB activation controls T cell longevity
Song, J., Salek-Ardakani, S., Rogers, P. R., Cheng, M., Van Parijs, L., & Croft, M. (2004) · Nature Immunology · doi:10.1038/ni1030 · Cited by 207
Guo, Z., Wang, X., Cheng, D., Xia, Z., Luan, M., & Zhang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089350 · Cited by 207
OX40 ligand shuts down IL-10-producing regulatory T cells
Ito, T., Wang, Y.-H., Duramad, O., Hanabuchi, S., Perng, O. A., Gilliet, M., Qin, F. X.-F., & Liu, Y.-J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603107103 · Cited by 198
The role of IL-22 and Th22 cells in human skin diseases
Fujita, H. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.04.028 · Cited by 197
Kjærgaard, J., Tanaka, J., Kim, J. A., Rothchild, K. B., Weinberg, A. D., & Shu, S. (2000) · PubMed · Cited by 197
Sanmamed, M. F., Pastor, F., Rodriguez, A., Perez-Gracia, J. L., Rodriguez-Ruiz, M. E., Jure-Kunkel, M., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.014 · Cited by 190
Costimulation of CD8 T Cell Responses by OX40
Bansal-Pakala, P., Halteman, B. S., Cheng, M. H.-Y., & Croft, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4821 · Cited by 175
Redmond, W. L., Linch, S. N., & Kasiewicz, M. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0031-t · Cited by 168
OX40–OX40 Ligand Interaction in T-Cell-Mediated Immunity and Immunopathology
Ishii, N., Takahashi, T., Soroosh, P., & Sugamura, K. (2010) · Advances in immunology · doi:10.1016/s0065-2776(10)05003-0 · Cited by 161
Shrimali, R. K., Ahmad, S., Verma, V., Zeng, P., Ananth, S., Gaur, P., Gittelman, R. M., Yusko, E., Sanders, C., Robins, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0292 · Cited by 161
Gough, M. J., Crittenden, M. R., Sarff, M., Pang, P., Seung, S. K., Vetto, J. T., Hu, H.-M., Redmond, W. L., Holland, J., & Weinberg, A. D. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee7095 · Cited by 160
OX40 is required for regulatory T cell–mediated control of colitis
Griseri, T., Asquith, M., Thompson, C., & Powrie, F. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091618 · Cited by 160
Foote, J. B., Kok, M., Leatherman, J. M., Armstrong, T. D., Marcinkowski, B. C., Ojalvo, L. S., Kanne, D. B., Jaffee, E. M., Dubensky, T. W., & Emens, L. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0284 · Cited by 160
Weinberg, A. D., BOURDETTE, D. N., Sullivan, T. J., Lemon, M., Wallin, J. J., Maziarz, R. T., Davey, M. P., Palida, F., Godfrey, W. R., Engleman, E. G., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-183 · Cited by 156
Lane, P. J. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.201 · Cited by 144
Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma
Hoshino, A., Tanaka, Y., Akiba, H., Asakura, Y., Mita, Y., Sakurai, T., Takaoka, A., Nakaike, S., Ishii, N., Sugamura, K., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200323455 · Cited by 143
OX40: Structure and function – What questions remain?
Willoughby, J. E., Griffiths, J., Tews, I., & Cragg, M. S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.01.006 · Cited by 143
Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis
Gourh, P., Arnett, F. C., Tan, F. K., Assassi, S., Divecha, D., Paz, G., McNearney, T. A., Draeger, H. T., Reveille, J. D., Mayes, M. D., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.116434 · Cited by 136
Constitutive OX40/OX40 Ligand Interaction Induces Autoimmune-Like Diseases
Murata, K., Nose, M., Ndhlovu, L. C., Sato, T., Sugamura, K., & Ishii, N. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4628 · Cited by 130
Zhang, X., Xiao, X., Lan, P., Li, J., Dou, Y., Chen, W., Ishii, N., Chen, S., Xia, B., Chen, K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.052 · Cited by 129
Montler, R. D., Bell, R. B., Thalhofer, C., Leidner, R. S., Feng, Z., Fox, B. A., Cheng, A. C., Bui, T. G., Tucker, C., Hoen, H. M., et al. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.16 · Cited by 128
Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention
Zhang, N., Pan, H., & Ye, D. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0772-y · Cited by 120
Lee, S., Myers, L. M., Muralimohan, G., Dai, J., Qiao, Y., Li, Z., Mittler, R. S., & Vella, A. T. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3002 · Cited by 120
OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice
Zaini, J., Andarini, S., Tahara, M., Saijo, Y., Ishii, N., Kawakami, K., Taniguchi, M., Sugamura, K., Nukiwa, T., & Kikuchi, T. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32693 · Cited by 117
Nohara, C., Akiba, H., Nakajima, A., Inoue, A., Koh, C., Ohshima, H., Yagita∥, H., Mizuno, Y., & Okumura, K. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.2108 · Cited by 116
Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation
Arestides, R. S. S., He, H., Westlake, R. M., Chen, A. I., Sharpe, A. H., Perkins, D. L., & Finn, P. W. (2002) · European Journal of Immunology · Cited by 110
Ndhlovu, L. C., Ishii, N., Murata, K., Sato, T., & Sugamura, K. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2991 · Cited by 109
OX40-OX40 Ligand Interaction through T Cell-T Cell Contact Contributes to CD4 T Cell Longevity
Soroosh, P., Ine, S., Sugamura, K., & Ishii, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5975 · Cited by 106
Murata, S., Ladle, B. H., Kim, P. S., Lutz, E. R., Wolpoe, M. E., Ivie, S. E., Smith, H. M., Armstrong, T. D., Emens, L. A., Jaffee, E. M., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.974 · Cited by 106
Morales‐Kastresana, A., Sanmamed, M. F., Rodríguez, I., Palazón, A., Martínez‐Forero, I., Labiano, S., Hervás‐Stubbs, S., Sangro, B., Ochoa, C., Rouzaut, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1189 · Cited by 105
Molecular mechanisms underlying Th1-like Treg generation and function
Kitz, A., & Dominguez‐Villar, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2569-y · Cited by 104
Tahiliani, V., Hutchinson, T. E., Abboud, G., Croft, M., & Salek‐Ardakani, S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601356 · Cited by 103
Zander, R., Obeng-Adjei, N., Guthmiller, J. J., Kulu, D., Li, J., Ongoïba, A., Traoré, B., Crompton, P. D., & Butler, N. S. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.03.007 · Cited by 99
Voo, K. S., Bover, L. C., Harline, M. L., Vien, L., Facchinetti, V., Arima, K., Kwak, L. W., & Liu, Y. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202752 · Cited by 99
Humphreys, I. R., Loewendorf, A. I., Trez, C. D., Schneider, K., Benedict, C. A., Munks, M. W., Ware, C. F., & Croft, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2195 · Cited by 97
Increased Serum Soluble OX40 in Patients with Systemic Sclerosis
Komura, K., Yoshizaki, A., Kodera, M., Iwata, Y., Ogawa, F., Shimizu, K., Wayaku, T., Yukami, T., MURATA, M., Hasegawa, M., et al. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080120 · Cited by 92
Cuadros, C., Dominguez, A. L., Lollini, P., Croft, M., Mittler, R. S., Borgström, P., & Lustgarten, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21098 · Cited by 91
Yokouchi, H., Yamazaki, K., Chamoto, K., Kikuchi, E., Shinagawa, N., Oizumi, S., Hommura, F., Nishimura, T., & Nishimura, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00664.x · Cited by 90
Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W. L., Yoshizawa, H., Yagita∥, H., Gejyo, F., Okumura, K., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903033 · Cited by 86
OX40 and Bcl-xL Promote the Persistence of CD8 T Cells to Recall Tumor-Associated Antigen
Song, A., Tang, X., Harms, K. M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3534 · Cited by 85
Saijo, S., Asano, M., Horai, R., Yamamoto, H., & Iwakura, Y. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10172 · Cited by 85
Radiation Therapy and Immunotherapy: What is the Optimal Timing or Sequencing?
Aliru, M. L., Schoenhals, J. E., Venkatesulu, B. P., Anderson, C., Barsoumian, H. B., Younes, A. I. A., Mahadevan, L. S. K., Soeung, M., Aziz, K. E., Welsh, J. W., et al. (2018) · Immunotherapy · doi:10.2217/imt-2017-0082 · Cited by 84
Jahan, N., Talat, H., & Curry, W. T. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox125 · Cited by 83
Lai, C., August, S., Albibas, A., Behar, R., Cho, S., Polak, M. E., Theaker, J. M., MacLeod, A. S., French, R. R., Glennie, M. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2614 · Cited by 82
Bossini‐Castillo, L., Broen, J. C. A., Simeón‐Aznar, C. P., Beretta, L., Vonk, M. C., Ortego‐Centeno, N., Espinosa, G., Carreira, P. E., Camps, M. T., Navarrete‐Navarrete, N., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.141838 · Cited by 80
Buchan, S. L., Manzo, T., Flutter, B. R., Rogel, A., Edwards, N., Zhang, L., Sivakumaran, S., Ghorashian, S., Carpenter, B., Bennett, C. L., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401644 · Cited by 79
Self-citationLinch, S. N., Kasiewicz, M. J., McNamara, M. J., Hilgart-Martiszus, I., Farhad, M. E., & Redmond, W. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510518113 · Cited by 79
Xiao, X., Shi, X., Fan, Y., Wu, C., Zhang, X., Minze, L. J., Liu, W., Ghobrial, R. M., Lan, P., & Li, X. C. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.013 · Cited by 79
Serghides, L., Bukczynski, J., Wen, T., Wang, C., Routy, J., Boulassel, M., Sékaly, R., Ostrowski, M., Bernard, N. F., & Watts, T. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.6368 · Cited by 73
IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival
Ruby, C. E., Montler, R. D., Zheng, R., Shu, S., & Weinberg, A. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2140 · Cited by 72
Dolff, S., Quandt, D., Wilde, B., Feldkamp, T., Hua, F., Cai, X., Specker, C., Kribben, A., Kallenberg, C. G. M., & Witzke, O. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3100 · Cited by 69
Carboni, S., Aboul‐Enein, F., Waltzinger, C., Killeen, N. P., Lassmann, H., & Rossi, C. P. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.07.001 · Cited by 64
Niknam, S., Barsoumian, H. B., Schoenhals, J. E., Jackson, H. L., Yanamandra, N., Caetano, M. S., Li, A., Younes, A. I. A., Cadena, A. P., Cushman, T. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3279 · Cited by 62
Anti-tumour therapeutic efficacy of OX40L in murine tumour model
Ali, S., Ahmad, M., Lynam, J., McLean, C. S., Entwisle, C., Loudon, P. T., Choolun, E., McArdle, S., Li, G., Mian, S., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.041 · Cited by 61
Th1-like Plasmodium-Specific Memory CD4+ T Cells Support Humoral Immunity
Zander, R., Vijay, R., Pack, A. D., Guthmiller, J. J., Graham, A. C., Lindner, S. E., Vaughan, A. M., Kappe, S. H. I., & Butler, N. S. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.077 · Cited by 61
Therapeutic effect of anti-OX40L and anti-TNF-α MAbs in a murine model of chronic colitis
Totsuka, T., Kanai∥, T., Uraushihara, K., Iiyama, R., YAMAZAKI, M., Akiba, H., Yagita∥, H., Okumura, K., & Watanabe, M. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00450.2002 · Cited by 60
Fc-mOX40L Fusion Protein Produces Complete Remission and Enhanced Survival in 2 Murine Tumor Models
Sadun, R. E., Hsu, W.-E., Zhang, N., Nien, Y.-C., Bergfeld, S. A., Sabzevari, H., Lutsiak, M. E. C., Khawli, L. A., Hu, P., & Epstein, A. L. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816a88e0 · Cited by 57
Pardee, A. D., McCurry, D., Alber, S. M., Hu, P., Epstein, A. L., & Storkus, W. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1369 · Cited by 57
Burocchi, A., Pittoni, P., Gorzanelli, A., Colombo, M. P., & Piconese, S. (2011) · European Journal of Immunology · doi:10.1002/eji.201141700 · Cited by 57
Stüber, Büschenfeld, Lüttges, Freier, V., Arendt, T., & Fölsch (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00658.x · Cited by 54
Redmond, W. L., Triplett, T., Floyd, K., & Weinberg, A. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034467 · Cited by 53
Cooperation between CD4 and CD8 T cells for anti‐tumor activity is enhanced by OX40 signals
Song, A., Song, J. J., Tang, X., & Croft, M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636957 · Cited by 52
Activation of OX40 Augments Th17 Cytokine Expression and Antigen-Specific Uveitis
Zhang, Z., Zhong, W., Hinrichs, D. J., Wu, X., Weinberg, A. D., Hall, M., Spencer, D., Wegmann, K. W., & Rosenbaum, J. T. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100353 · Cited by 51
Self-citationFunctional characterization of OX40 expressed on human CD8+ T cells
Fujita, T., Ukyo, N., Hori, T., & Uchiyama, T. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.04.001 · Cited by 51
Activated T cells express the OX40 ligand: requirements for induction and costimulatory function
Mendel, I., & Shevach, E. M. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02279.x · Cited by 48
Coexpression of CD25 and OX40 (CD134) Receptors Delineates Autoreactive T-cells in Type 1 Diabetes
Endl, J., Rosinger, S., Schwarz, B., Friedrich, S. O., Rothe, G., Karges, W., Schlosser, M., EIERMANN, T. H., Schendel, D. J., & Boehm, B. O. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0387 · Cited by 48
Sitrin, J., Suto, E., Wüster, A., Eastham‐Anderson, J., Kim, J. M., Austin, C. D., Lee, W. P., & Behrens, T. W. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700608 · Cited by 46
OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age
Ruby, C. E., & Weinberg, A. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1481 · Cited by 44
Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment
Bresson, D., Fousteri, G., Manenkova, Y., Croft, M., & von Herrath, M. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.10.001 · Cited by 41
Boettler, T., Choi, Y. S., Salek‐Ardakani, S., Cheng, Y., Moeckel, F., Croft, M., Crotty, S., & von Herrath, M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300013 · Cited by 38
Dong, W., & Zhu, P. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.02.019 · Cited by 35
TNF superfamily cytokines in the promotion of Th9 differentiation and immunopathology
Meylan, F., & Siegel, R. M. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0612-y · Cited by 33
OX40 promotes obesity-induced adipose inflammation and insulin resistance
Liu, B., Yu, H., Sun, G., Sun, X., Jin, H., Zhang, C., Shi, W., Tian, D., Liu, K., Xu, H., et al. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2552-7 · Cited by 32
Negative regulation of IL-17 production by OX40/OX40L interaction
Li, J. J., Li, L., Shang, X., Benson, J., Elloso, M. M., Schantz, A., Bracht, M., Orlovsky, Y. I., & Sweet, R. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2008.04.010 · Cited by 31
Critical role of OX40 in the expansion and survival of CD4 T-cell-derived double-negative T cells
Sun, G., Sun, X., Li, W., Liu, K., Tian, D., Dong, Y., Sun, X., Xu, H., & Zhang, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0659-x · Cited by 27
Association of the co-stimulator OX40L with systemic lupus erythematosus
Manku, H., Graham, D. S. C., & Vyse, T. J. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0431-2 · Cited by 23
Kovacsovics-Bankowski, M., Chisholm, L., Vercellini, J., Crittenden, M. R., Lary, S., Curti, B. D., & Weinberg, A. D. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-s1-p255 · Cited by 21
Activation of OX40 Prolongs and Exacerbates Autoimmune Experimental Uveitis
Wu, X., Rosenbaum, J. T., Adamus, G., Zhang, G. L., Duan, J., Weinberg, A. D., & Zhang, Z. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7664 · Cited by 15
Self-citationFujiwara, S., Nagai, H., Shimoura, N., Oniki, S., Yoshimoto, T., & Nishigori, C. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.42 · Cited by 12
Bassett, J. D., Swift, S. L., VanSeggelen, H., Hammill, J. A., McGray, A. R., Evelegh, C. M., Wan, Y., & Bramson, J. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.281 · Cited by 11
Mattsson, L.-Å., Lundberg, K., Müssener, E., JANSSON, A., Harris, H. E., & Larsson, P. T. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02054.x · Cited by 7
Activation of the Ras-related GTPase Rap1 by thymocyte TCR engagement and during selection
(2000) · Pure Amsterdam UMC · doi:10.1002/1521-4141(200010)30:10 · Cited by 3
Cited by
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J. S., Rajagopal, S., Pai, A. R., & Kutty, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01648 · Cited by 511
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Ding, C., Song, Z., Shen, A., Chen, T., & Zhang, A. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.03.001 · Cited by 306
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Metadata
- Authors
- Fu, Y., Lin, Q., Zhang, Z., & Zhang, L.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 10
- Issue
- 3
- Pages
- 414-433
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W2972242424
- Cited by
- 260
- References
- 128
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.